- Home
- GBX vs GLPG Comparison
GBX vs GLPG Comparison
Compare GBX & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBX
- GLPG
- Stock Information
- Founded
- GBX 1974
- GLPG 1999
- Country
- GBX United States
- GLPG Belgium
- Employees
- GBX N/A
- GLPG N/A
- Industry
- GBX Railroads
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- GBX Industrials
- GLPG Health Care
- Exchange
- GBX Nasdaq
- GLPG Nasdaq
- Market Cap
- GBX 1.8B
- GLPG 1.8B
- IPO Year
- GBX N/A
- GLPG 2005
- Fundamental
- Price
- GBX $44.36
- GLPG $25.32
- Analyst Decision
- GBX Hold
- GLPG Sell
- Analyst Count
- GBX 2
- GLPG 4
- Target Price
- GBX $57.00
- GLPG $25.33
- AVG Volume (30 Days)
- GBX 464.3K
- GLPG 466.6K
- Earning Date
- GBX 07-07-2025
- GLPG 04-23-2025
- Dividend Yield
- GBX 2.86%
- GLPG N/A
- EPS Growth
- GBX 85.75
- GLPG N/A
- EPS
- GBX 6.26
- GLPG N/A
- Revenue
- GBX $3,511,200,000.00
- GLPG $311,493,731.00
- Revenue This Year
- GBX N/A
- GLPG N/A
- Revenue Next Year
- GBX N/A
- GLPG N/A
- P/E Ratio
- GBX $7.14
- GLPG N/A
- Revenue Growth
- GBX N/A
- GLPG 18.32
- 52 Week Low
- GBX $37.77
- GLPG $22.36
- 52 Week High
- GBX $71.06
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- GBX 48.25
- GLPG 45.40
- Support Level
- GBX $42.49
- GLPG $25.20
- Resistance Level
- GBX $45.27
- GLPG $27.64
- Average True Range (ATR)
- GBX 1.21
- GLPG 0.59
- MACD
- GBX 0.69
- GLPG -0.09
- Stochastic Oscillator
- GBX 77.25
- GLPG 23.93
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of revenue from the United States.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.